• shutterstock_123513190
  • slide1
  • slide2

ABOUT US

CMC Contrast  AB is a privately owned drug development company developing CMC-001, a novel contrast agent for use in liver MRI.

PIPELINE

CMC-001 is an investigational new drug for diagnostic use as a MRI contrast agent for enhancement of the liver. 

INVESTORS

The three investors behind CMC Contrast AB is Sunstone Capital, Industrifonden and ├śresund Healthcare.